Immunosuppressive activity of abatacept on Circulating T helper lymphocytes from juvenile idiopathic arthritis patients

International Archives of Allergy and Immunology

Volumn 171, Issue 1, 2016, Pages 45-53

  Maggi, Laura ^a   Cimaz, Rolando ^b   Capone, Manuela ^a   Santarlasci, Veronica ^a   Rossi, Maria Caterina ^a   Mazzoni, Alessio ^a   Montaini, Gianni ^a   Pagnini, Ilaria ^b   Giani, Teresa ^b   Simonini, Gabriele ^b   Scaletti, Cristina ^a   Liotta, Francesco ^a   Maggi, Enrico ^a   Annunziato, Francesco ^a   Cosmi, Lorenzo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biological therapy; CD4+ T cells; Cytokines

Indexed keywords

ABATACEPT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; PREDNISONE; TUMOR NECROSIS FACTOR; ANTIGEN; AUTACOID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; JUVENILE RHEUMATOID ARTHRITIS; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, JUVENILE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE SUBPOPULATION;

ABATACEPT; ADOLESCENT; ANTIGENS; ARTHRITIS, JUVENILE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CHILD; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MALE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84994714127     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000450948     Document Type: Article

References (25)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369: 767-778
2. Murray KJ, Luyrink L, Grom AA, Passo MH, Emery H, Witte D, Glass DN. Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis. J Rheumatol 1996; 23: 2116-2124
3. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, Liotta F, Maggi E, Romagnani S, Annunziato F. Human interleukin-17-producing cells originate from a CD161+ CD4+ T-cell precursor. J Exp Med 2008; 205: 1903-1916
4. Cosmi L, Cimaz R, Maggi L, Santarlasci V, Capone M, Borriello F, Frosali F, Querci V, Simonini G, Barra G, Piccinni MP, Liotta F, De Palma R, Maggi E, Romagnani S, Annunziato F. Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 2504-2515
5. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo controlled trial. N Engl J Med 1992; 326: 1043-1049
6. Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum 2013; 42: 597-618
7. Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, Tincani A, Airo P. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol 2014; 41: 666-672
8. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-391
9. Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 2013; 72: 1806-1812
10. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991-1994
11. Maggi L, Cimaz R, Capone M, Santarlasci V, Querci V, Simonini G, Nencini F, Liotta F, Romagnani S, Maggi E, Annunziato F, Cosmi L. Brief report: etanercept inhibits the tumor necrosis factor a-driven shift of Th17 lymphocytes toward a nonclassic Th1 phenotype in juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66: 1372-1377
12. Betjes MGH: Clinical consequences of circulating CD28-negative T cells for solid organ transplantation. Transpl Int 2016; 29: 274-284
13. Goldzweig O, Hashkes PJ. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther 2011; 5: 61-70
14. Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol 2015; 36: 63-70
15. Ndejembi MP1, Teijaro JR, Patke DS, Bingaman AW, Chandok MR, Azimzadeh A, Nadler SG, Farber DL. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006; 177: 7698-7706
16. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-769
17. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096-1103
18. Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven RV, Malmstrom V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013; 14: 34
19. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S. Phenotype, localization, and mechanism of suppression of CD4 + CD25 + human thymocytes. J Exp Med 2002; 196: 379-387
20. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440
21. Charbonniera LM, Vokaera B, Lemaitrea PH, Fieldb KA, Leoa O, Le Moinea A. CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells. Am J Transpl 2012; 12: 2313-2321
22. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L, Juarez-Reyes A, Monsivais-Urenda A, Baranda L, Gonzalez-Amaro R. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31: 588-595
23. Picchianti Diamanti A, Rosado MM, Scarsella M, Germano V, Giorda E, Cascioli S, Lagana B, D'Amelio R, Carsetti R. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-Tumour necrosis factor-A agents. Clin Exp Immunol 2014; 177: 630-640
24. Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010; 62: 1542-1551
25. Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess 2016; 34: 1-222